Surrozen, Inc. (SRZN)
NASDAQ: SRZN · Real-Time Price · USD
29.32
-0.68 (-2.27%)
At close: Oct 2, 2026, 4:00 PM EDT
29.89
+0.57 (1.94%)
After-hours: Oct 2, 2026, 7:48 PM EDT
Surrozen Revenue
Surrozen had revenue of $5.00M in the quarter ending June 30, 2026, with 408.65% growth. This brings the company's revenue in the last twelve months to $11.51M, down -8.79% year-over-year. In the year 2025, Surrozen had annual revenue of $3.48M, down -67.37%.
Revenue (ttm)
$11.51M
Revenue Growth
-8.79%
P/S Ratio
29.94
Revenue / Employee
$261,614
Employees
44
Market Cap
344.61M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.48M | -7.18M | -67.37% |
| Dec 31, 2024 | 10.66M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 12.50M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Enanta Pharmaceuticals | 65.26M |
| Fennec Pharmaceuticals | 59.22M |
| vTv Therapeutics | 36.84M |
| C4 Therapeutics | 35.04M |
| Orchestra BioMed Holdings | 31.98M |
| Arcturus Therapeutics Holdings | 29.37M |
| Ocugen | 4.58M |
| Inhibikase Therapeutics | 1.00 |
SRZN News
- 21 hours ago - Surrozen announces FDA clearance of IND application for SZN-8141 - TheFly
- 21 hours ago - Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema - GlobeNewsWire
- 7 days ago - Surrozen price target raised to $54 from $44 at H.C. Wainwright - TheFly
- 16 days ago - Surrozen Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 22 days ago - Surrozen Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 24 days ago - Surrozen submits investigational new drug application for SZN-8141 - TheFly
- 24 days ago - Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema - GlobeNewsWire
- 4 weeks ago - Surrozen Slides: Corporate presentation - Filings